Area of research
Hematology · Radiology, Nuclear Medicine and Imaging
Research interest
Research interests include Multiple Myeloma Research and Treatments, Monoclonal and Polyclonal Antibodies Research, Protein Degradation and Inhibitors, and Chronic Lymphocytic Leukemia Research.
Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1–2 study
Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab
Randomized, multi-center study of carfilzomib, lenalidomide, and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM): The ADVANCE clinical trial.
Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma
Linvoseltamab in Patients With Relapsed/Refractory Multiple Myeloma in the LINKER-MM1 Study: Longer Follow-Up and Subgroup Analyses
Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma
Talquetamab Versus Real-World Physician's Choice Treatment: Comparative Effectiveness in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma.
Patterns of Response to 200 Mg Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-Up of the Linker-MM1 Study
The role of biomarkers in personalized immunotherapy
Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting